1-4 of 4
Takeshi Sagara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 in vivo can be overcome by HER2 inhibition with TAS0728

Hiroki Irie, Rumi Kawabata, Yayoi Fujioka, Fumio Nakagawa, Hideki Nagase, Hiraku Itadani, Kimihiro Ito, Junji Uchida, Shuichi Ohkubo, Kenichi Matsuo, Takeshi Sagara, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A126.
https://doi.org/10.1158/1535-7163.TARG-19-A126
Published: 01 December 2019
View article titled, Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 <em>in vivo</em> can be overcome by HER2 inhibition with TAS0728
Journal Articles

Abstract A063: TAS1553, a novel class of RNR inhibitor, demonstrates synergistic antitumor efficacy in combination with nucleoside analogues

Takuya Hoshino, Hiroyuki Ueno, Wakako Yano, Sayaka Tsukioka, Seiji Miyahara, Takamasa Suzuki, Kazutaka Miyadera, Teruhiro Utsugi, Takeshi Sagara
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A063.
https://doi.org/10.1158/1535-7163.TARG-19-A063
Published: 01 December 2019
View article titled, Abstract A063: TAS1553, a novel class of RNR inhibitor, demonstrates synergistic antitumor efficacy in combination with nucleoside analogues
Journal Articles

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Hiroki Irie, Kei Oguchi, Kimihiro Ito, Yayoi Fujioka, Yuichi Kawai, Tadashi Shimamura, Hikari Araki, Akio Fujioka, Fumio Nakagawa, Rumi Kawabata, Hideki Nagase, Takeshi Sagara, Junji Uchida, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazu Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B179.
https://doi.org/10.1158/1535-7163.TARG-17-B179
Published: 01 January 2018
View article titled, Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
Journal Articles

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada, Tsuyoshi Arai, Toshihide Nishibata, Makiko Kobayashi, Toshifumi Kimura, Naoki Kaneko, Junko Ohtani, Kazunori Yamanaka, Hiraku Itadani, Ikuko Takahashi-Suzuki, Kazuhiro Fukasawa, Hiroko Oki, Tadahiro Nambu, Jian Jiang, Takumi Sakai, Hiroharu Arakawa, Toshihiro Sakamoto, Takeshi Sagara, Takashi Yoshizumi, Shinji Mizuarai, Hidehito Kotani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 2992–3000.
https://doi.org/10.1158/1535-7163.MCT-09-0463
Published: 10 November 2009
View article titled, Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Open the PDF for Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents in another window
Includes: Supplementary data